CEPI and SK bioscience partner to advance mRNA vaccine technology
CEPI will provide up to US$40 million in initial funding to support the development of mRNA-vaccine candidates against Lassa Fever virus
CEPI will provide up to US$40 million in initial funding to support the development of mRNA-vaccine candidates against Lassa Fever virus
Pluvicto and Scemblix launches are progressing well and we are awaiting data in earlier lines of therapy.
Micafungin for Injection had annual sales of US $99 million in the United States according to IQVIA data
The global VR market to grow at a compound annual growth rate of 13% from $7 billion in 2018 to $28 billion in 2030.
Paliperidone Extended-Release Tablets (RLD Invega) had estimated annual sales of USD 112 million in the U.S. (IQVIA MAT August 2022).
Separate Phase 3 study evaluating 200 days of therapy with PREVYMIS in HSCT recipients at high risk of late clinically significant CMV infection recently completed, meeting its primary endpoint
The company has reported total income of Rs. 1612.60 crores during the period ended September 30, 2022.
The company has reported total income of Rs. 519.31 crores during the period ended September 30, 2022.
A MoU was signed between Ministry of Ayush and Ministry of Tribal Affairs to collaborate in Ayush sector
Tech-driven calculator, which serves as a preventive tool that helps in heart risk assessment using several factors
Subscribe To Our Newsletter & Stay Updated